CTLA4 and colon carcinoma: We decided to investigate the antitumor activity of IL-2cx (2 μg IL-2/dose) either alone or in combination with ICIs (anti-CTLA-4 plus anti-PD-1 antibodies) using the CT26 mouse colon carcinoma model (figure 3A).